Clinical perspectives of PSMA PET/MRI for prostate cancer by Barbosa, Felipe de Galiza et al.
Clinical perspectives of PSMA PET/MRI for prostate
cancer
Felipe de Galiza Barbosa,I,* Marcelo Arau´jo Queiroz,I,II Rafael Fernandes Nunes,I Jose´ Fla´vio Gomes Marin,I,II
Carlos Alberto Buchpiguel,I,II Giovanni Guido CerriI,II
IDepartamento de Radiologia, Hospital Sirio-Libanes, Sao Paulo, SP, BR. II Instituto de Radiologia, Hospital das Clinicas HCFMUSP, Faculdade de Medicina,
Universidade de Sao Paulo, Sao Paulo, SP, BR.
Barbosa FG, Queiroz MA, Nunes RF, Marin JF, Buchpiguel CA, Cerri GG. Clinical perspectives of PSMA PET/MRI for prostate cancer. Clinics. 2018;
73(suppl 1):e586s
*Corresponding author. E-mail: felipegaliza@gmail.com
Prostate cancer imaging has become an important diagnostic modality for tumor evaluation. Prostate-specific
membrane antigen (PSMA) positron emission tomography (PET) has been extensively studied, and the results are
robust and promising. The advent of the PET/magnetic resonance imaging (MRI) has added morphofunctional
information from the standard of reference MRI to highly accurate molecular information from PET. Different
PSMA ligands have been used for this purpose including 68gallium and 18fluorine-labeled PET probes, which
have particular features including spatial resolution, imaging quality and tracer biodistribution. The use of
PSMA PET imaging is well established for evaluating biochemical recurrence, even at low prostate-specific anti-
gen (PSA) levels, but has also shown interesting applications for tumor detection, primary staging, assessment of
therapeutic responses and treatment planning. This review will outline the potential role of PSMA PET/MRI for
the clinical assessment of PCa.
KEYWORDS: Prostate Cancer; Positron Emission Tomography/Magnetic Resonance Imaging; Diagnostic Imaging;
Tumor Staging; Local Neoplasm Recurrence.
’ INTRODUCTION
Prostate cancer (PCa) faces a new era of diagnosis and manage-
ment with the use of next-generation imaging modalities
based on positron emission tomography (PET). The advent
of prostate-specific membrane antigen (PSMA) PET tracers
has increased the clinical application of imaging diagnosis
of PCa in different clinical settings, such as for primary
staging, detection of biochemical recurrence (BCR), assess-
ment of therapeutic responses and treatment planning.
In Brazil, there were an estimated 61200 new cases of PCa
in 2016, making PCa the second most prevalent neoplasia
among men throughout the country and the third most com-
mon cause of cancer-associated mortality in men in Western
countries (1,2).
PSMA is a type II transmembrane glycoprotein that is
highly expressed in almost all PCa cells, with only 5-10% of
primary PCa not having PSMA expression (3). PSMA PET
positivity has been shown to increase with higher tumor
stage and grade, higher prostate-specific antigen (PSA) levels
and doubled time (4). Several studies have addressed the
clinical impact of PSMA PET for PCa assessment, for
primary staging, restaging/biochemical recurrence, radio-
therapy planning and systemic therapy planning in patients
who have previously undergone salvage treatment (5-8). Only
one PSMA ligand has been approved by the Food and Drug
Administration (FDA), the radiolabeled anti-PSMA antibody
capromab pendetide (ProstaScint), which has a low accuracy
for PCa detection, as it is a large antibody that binds to
the intracellular domain of PSMA (9). On the other hand,
there are a few small molecules PSMA ligands that bind to the
active site in the extracellular domain of PSMA thus providing
increased tumor uptake and high image quality (3).
The two first PSMA agents for PET imaging were 18F-DCFBC
and 68Ga-PSMA-11, followed by another two probes with
theranostic capabilities, the chelator-based PSMA-617 and
the PSMA inhibitor for imaging and therapy PSMA-I&T.
Later, some second-generation 18F-labeled PSMA ligands were
introduced to overcome the high blood-pool activity and low
tumor-to-background ratios of 18F-DCFBC, namely, 18F-DCFPyL
and, more recently, 18F-PSMA-1007, which has very low urine
clearance (3,9). All of these PET agents have already been
translated to clinical applications and some have been used in
PET/magnetic resonance imaging (MRI) systems.
The combination of structural, multiparametric functional,
and molecular information of PSMA PET/MRI might represent
a breakthrough for PCa evaluation. PET/MRI has shown
superiority over PET/CT using a 68Ga-labeled PSMA for the
detection of recurrent PCa; however, this modality has limita-
tions regarding scatter correction (10). Some case reports have
shown this potential advantage of PET/MRI in differentDOI: 10.6061/clinics/2018/e586s
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clinical scenarios, such as for the diagnosis of primary tumors
(11,12). It is believed that the use of PET/MRI might facilitate
biopsy targeting, prediction/monitoring of tumor aggressive-
ness (especially for active surveillance) and radiation therapy
planning (e.g., boost for a dominant intraprostatic lesion) (12).
For the proper clinical use of PET/MRI using PSMA agents,
the workflow must be strictly optimized; an adequate protocol
must be defined to avoid redundant information and long
acquisition times. Nevertheless, it is mandatory to include
high-resolution T2-weighted sequences combined with diffu-
sion-weighted imaging (DWI) and perfusion on the MRI por-
tion of the scan. The standard PET scan lasts 60 minutes, and
there is an arguable advantage of performing either an early
or a late acquisition.
This review will highlight the clinical perspectives of
the use of PET/MRI with PSMA ligands for evaluating PCa
including local detection, primary staging, identification of BCR,
assessment of therapeutic responses and therapy planning.
Local detection and primary staging
More than 90% of primary PCa lesions show moderate to
high PSMA expression levels on PSMA PET (13), and many
current studies have indicated that PET/MRI could be the
single ideal imaging modality for staging PCa patients
(10,14,15). There are already proposed protocols that are
potentially viable for routine clinical application that have
Prostate Imaging Reporting and Data System (PI-RADS)
2.0-compliant multiparametric MRI acquisitions of the pros-
tate bed and whole-body PSMA PET (15).
The MRI component is the imaging modality of choice
for precise morphologic evaluation and has higher spatial
resolution and provides clearer anatomic delineation of the
prostatic fossa and surrounding anatomical structures than
PET (16), while PSMA PET is the superior modality for detect-
ing metastases to the locoregional and extrapelvic lymph
nodes, bones and visceral organs (17).
Consequently, PSMA PET/MRI yields greater diagnostic
accuracy for PCa localization than multiparametric MRI
(mpMRI) or PET alone. These encouraging data indicate that
hybrid imaging using morphologic, functional, and molecular
information enhances diagnostic performance in patients with
PCa for TNM staging (14) (Figure 1).
T Staging. MRI brings valuable conveniences over PET/
CT due to the high soft tissue contrast and offers the advan-
tages of functional MRI techniques (16). In turn, PSMA PET
has a very specific molecular imaging target for PSMA-
expressing tumors. Each imaging modality alone is capable
of identifying tumor sites that would otherwise be missed or
considered negative by the other technique. Thus, PSMA
PET/MRI has higher sensitivity (76%) than either method
used alone (58% and 64%) (14).
Diffusion-weighted and dynamic contrast-enhanced (DCE)
MRI have potential to furnish biological characterization
of tumor aggressiveness in PCa patients. Recent data have
associated quantitative MRI parameters with Gleason score
and tumor angiogenesis (18). Likewise, studies have indicated
that the intensity of radiotracer accumulation in the primary
tumor is correlated to PSA levels and Gleason score (i.e., the
higher the PSA levels, Gleason scores and d’Amico risk scores
are, the greater the PSMA uptake on PET) (19,20). The sum of
these parameters could provide details about distinct tumor
aggressiveness in different regions throughout the prostate
gland and even within the same lesion. Accordingly, aggregat-
ing information regarding PSMA uptake, lesion cellularity,
vascular permeability and contrast media kinetics has brought
about rich data for tumor characterization (21). This is of parti-
cular relevance when considering the potential role of PSMA
PET/MRI as a prebiopsy diagnostic tool that can be used
to guide sampling of the most aggressive sites. Hence, this
method could be indicated for detecting intraprostatic malig-
nant lesions in untreated patients with newly diagnosed PCa (20).
Figure 1 - PSMA PET/MRI for initial staging of a 77-year-old high-risk PCa patient with a Gleason score of 7 (3+4) and a PSA of 44.0 ng/dL.
The staging would be T3bN1M0 if the patient was assessed with conventional imaging, namely, mpMRI (B and D) and BS (F). PSMA PET
(coronal maximum intensity projection (MIP)inf A and fused PET/MR in C and E) clearly depicts more extensive pelvic (white arrows in A),
extrapelvic thoracic and right inferior cervical nodal involvement (black arrows in A), upstaging the patient to T3bN1M1a. The incre-
mental value of multimodal assessment is also seen in terms of the patient’s T status. There is concordance between PSMA PET and
MRI regarding bilateral seminal vesicle involvement encompassing the whole right seminal vesicle and the medial portion of the left
seminal vesicle (white arrowheads in B and C), whereas PSMA PET/MRI revealed a more extensive (black long arrow in E) primary lesion
in the left and median peripheral zones of base and midgland than mpMRI (white long arrows in D and E).
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Regarding evaluation of tumor extent and extracapsular
and seminal vesicle invasion, studies have shown promising
results with PSMA PET. These parameters are major con-
cerns for treatment planning. Curative surgery is possible
when none of these findings is present. Nerve-sparing
surgical techniques might not be performed in men with extra-
capsular extension, leading to increased risk of urinary incon-
tinence and erectile dysfunction after prostatectomy, mainly
when a bilateral technique is employed. These factors also
have a profound impact on prognostication, since extracap-
sular extension and seminal vesicle invasion are both related
to an increased risk of recurrence and lymph node and bone
metastases. PSMA PET/MRI can have an important impact
for local staging of PCa prior to radical prostatectomy (22).
Finally, addition of the PET component could address
two relatively common shortcomings of MRI by reducing the
limitation of evaluating patients who have recently undergone
recent biopsies and increasing the performance for assessing
transition zone (TZ) lesions. With regard to the first issue,
whereas functional MRI techniques, such as DCE and DWI,
could potentially be flawed with pitfalls and artifacts due
to prior biopsy, PSMA PET does not appear to be impaired
by those issues (21). Regarding the second matter, imaging
of cancer lesions in the TZ may be confounded with other
conditions on MRI, especially benign prostatic hypertrophy.
While the peripheral zone is the most common site of PCa
where 75–85% of lesions are located, as many as 25% of
patients might develop tumors in the TZ. Hence, tumors in
the TZ of the prostate are often missed by MRI alone, increas-
ing the need for an additional method of detecting PCa in
this location, and this need can be fulfilled by identifying the
presence or absence of PSMA uptake (23).
Multimodal evaluation might facilitate biopsy orientation
and lead to an impact on management, especially for predict-
ing and monitoring tumor aggressiveness during active surveil-
lance, determining more important targets when planning
radiation therapy (dose escalations within a prostate clinical
target volume) (24) and planning appropriate surgical tech-
nique and intraoperative management.
N Staging. PSMA PET is decidedly superior to MRI
in terms of identifying distant metastases in patients with
intermediate to high-risk PCa. As the method becomes more
present in clinical settings, presumably many patients who are
staged as N0 or M0 by current imaging evaluation will be more
accurately staged as N1 or M1 (6,24). Pretreatment staging with
PSMA PET has the potential to be established as the standard
of care for imaging in these patients since the success of therapy
relies on precise inclusion of involved sites would remain
untreated when staging with conventional imaging (24).
Involved lymph nodes are diagnosed by MRI when
morphologic changes such as enlargement or round shape
are present, while PSMA PET can demonstrate metastasis
based on tracer uptake in morphologically unremarkable lymph
nodes as small as 2 mm (13), even though this modality is also
influenced by nodal size (25). A recent study reported that
PSMA PET scans revealed previously unknown nodal involve-
ment in 39% of the patients (6). Additionally, combination of
PSMA PET with mpMRI is a promising path for improv-
ing the capabilities of PET to the greatest extent and ulti-
mately resulting in better determination of nodal status (24).
A recent template-based analysis study including 130 patients
revealed that the sensitivity, specificity and accuracy of PSMA
PET were 68.3%, 99.1% and 95.2%, respectively, while for
morphological imaging the sensitivity, specificity and accu-
racy were 27.3%, 97.1% and 87.6%, respectively (13).
This is of paramount importance when curative local
treatment of the prostate is considered, especially for planning
external radiation therapy and surgical resection. With PSMA
PET, a large number of patients may benefit from dramatic
changes in the contouring of the targeted volumes and in the
prescribed dose of radiation therapy. PSMA positive nodes
tend to receive higher doses than the adjacent pelvic nodal
volumes. Additionally, clinical target volume (CTV) can be
extended to treat areas of disease that were not identified by
conventional studies or targeted by consensus CTVs (24).
M Staging. In intermediate and high-risk PCa patients,
the current preoperative staging for bone metastases includes
MRI/CT and bone scintigraphy.
As 99mTc-MDP displays osteoblastic activity, this modality
demonstrates uptake in areas of degenerative and inflam-
matory diseases and fractures resulting in a low specificity for
metastases (26). A recent investigation including 126 patients
revealed a sensitivities and specificities for secondary osseous
involvement of 98.7-100% and 88.2-100%, respectively, for
PSMA PET and 86.7-89.3% and 60.8-96.1%, respectively, for
bone scan (BS) (27). Another recent study reported that PSMA
PET scans revealed previously unknown distant metastatic
disease in 16% of patients (6).
Assessment of whole-body osseous tumor burden has
also been proposed in recent studies investigating the role
of PSMA PET as an exploratory imaging technique for prog-
nostication and evaluation of potential objective responses (28).
The primary therapy for metastatic disease is androgen
deprivation therapy. However, it is controversial among many
clinicians if a distinct treatment approach should be made
for patients with limited metastatic disease (oligometastatic)
compared with those with diffuse metastatic disease. Stereo-
tactic radiosurgery and metastatectomy with or without andro-
gen deprivation therapy are being investigated in numerous
studies (29). Therefore, correct identification of these patients
is gaining importance, and PSMA PET imaging has emerged
as an important technique in this scenario (24).
Finally, other distant lesions including visceral and soft
tissue metastases that can easily be missed by conventional
investigation are potentially detectable with the whole-body
technique; in particular, pulmonary (10,20), genital and soft
tissue lesions can be detected with this method (20,30).
Biochemical recurrence
PCa relapse after curative intent treatment (prostatectomy
or radiation therapy) is defined as BCR, which is diagnosed
by an increased PSA level. Up to 40% of patients develop
BCR during their lifetime, and approximately 25% develop
clinical recurrence after 7-8 years (31). Detecting specific BCR
sites with imaging has been a challenging for the last 10 years,
even with the development of dedicated MRI. Disease detec-
tion is clinically relevant because it can guide more effective
treatment planning and consequently avoid futile systemic or
localized treatment approaches and their related side effects (32).
PCa is a slowly recurrent disease in majority of patients;
thus, detecting very low volume disease in the BCR scenario
is important due to the possibility of salvage treatment
(surgery or radiotherapy), postponement of systemic andro-
gen deprivation treatment (ADT), or even cure (33). The uro-
logical community suggests that with this treatment approach
patients may have prolonged and improved quality of life;
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however, long-term patient outcomes with this approach still
need to be demonstrated.
Current conventional imaging modalities (bone scintigra-
phy and computed tomography (CT)) have low accuracy for
pelvic node and bone metastasis in patients with low PSA
levels (31). MRI has become the method of choice for local
recurrence, with a sensitivity of approximately 75%. Although
MRI performs better than conventional imaging, identifying
local recurrence is the least important for making changes to
salvage treatment, as radiation therapy of the prostate bed is
the first indicated method for BCR in patients with low PSA
levels (32).
PSMA PET/CT has become the breakthrough imaging
method for PCa relapse in the last 5 years (34). The literature
has demonstrated that PSMA has better sensitivity and speci-
ficity than conventional methods or choline PET for detecting
tumor recurrence, especially in patients with low PSA levels
(o1.0 ng/mL) (35,36). The sensitivity rates of PSMA PET/
CT according to PSA levels are 55-60% (0.2-0.5 ng/mL),
72-75% (0.5-1.0 ng/mL), 93% (1.0-2.0 ng/mL) and 97%
(X2.0 ng/mL). A recent study of PET/MR showed a higher
detection rate in patients with very low PSA levels than those
of other PET/CT studies in the literature, with detection rates
of 44% (o0.2 ng/mL) and 72.7% (0.2-0.5 ng/mL) (37). These
findings can be explained by the higher sensitivity of PET
detectors in PET/MRI system and/or due to higher resolu-
tion imaging in the prostate bed. Clinical parameters that can
influence also detection of BCR are high PSA levels (41.0
ng/mL), short PSA doubling time (o6 months) and high
Gleason score (X8), all of which increase the detectability
rate of BCR on PSMA PET (4,38) (Figure 2).
PCa recurrence has a less predictable pattern of spread
than imaging before PSMA. The most commonly detected
sites of BCR are the abdominopelvic lymph nodes (50-55%),
supradiaphagmatic lymph nodes (5.2%), bones (35.9%),
local recurrence (35.1%) and other organs (e.g., lung, liver)
with 5.2% (4). Different than was previously thought, nodal
recurrence is more common than local recurrence and not
only involves usual lymph node stations (obturator, external
iliac, internal iliac and common iliac) but also involves
atypical pelvic atypical. Mesorectal lymph node involvement
is one of the most common atypical nodal stations in the
pelvis, with 15.8% detection rate according to Hijazi et al. (39).
As demonstrated in some studies (4,39), PSMA PET/CT can
detect lymph nodes that measure less than 5 mm in the short-
axis diameter, explaining its better sensitivity for nodal detec-
tion than CT or MRI. Regarding systemic spread of PCa to
bone, few papers have demonstrated the clear superiority of
PSMA PET for detecting bone lesions compared to bone scinti-
graphy (BS), and that BS did not have significant additional
diagnostic value in BCR scenario (27,40,41). However, focal
bone PSMA uptake alone should not be immediately con-
sidered metastasis; moreover, if moderate/mild uptake, which
has to be correlated with CT morphology, is noted, it can
decrease the possibility of false positives (40), as a few cases of
benign lesions with PSMA uptake have been reported (42,43).
Literature has confirmed the abovementioned findings,
which have deep clinical implications. As recommended in
current guidelines, a negative conventional imaging evalua-
tion suggests that a patient is suitable for salvage radio-
therapy of the prostate bed; however, PSMA imaging could
significantly change treatment decisions by detecting small
pelvic lymph nodes or bone metastasis. Recent study by
Hope et al. has shown that PSMA imaging had a significant
impact for evaluating BCR in 53% of patients and led to
major changes in management and avoided unnecessary
imaging studies (BS, CT and MRI) and invasive procedures (5).
In this study, most of the major changes involved conversion
Figure 2 - Evaluation of BCR in a 68-year-old patient treated with prostatectomy with a Gleason 7 adenocarcinoma (8 years) and
prostate bed radiation (3 years), with a current PSA level of 0.29 ng/ml. 68Ga-PSMA-fused PET/MRI MIP images (A) demonstrated 2
pathologic areas of focal uptake in the pelvis (black arrows). Axial T2-weighted imaging (B) showed nonspecific bilateral hypointense
tissue in the prostate bed (arrowheads); however, T1-weighted perfusion imaging (C) demonstrated hypervascularity in the left tissue
(arrowhead), which also had focal PSMA uptake on fused PET/MR imaging (D), confirming local recurrence. Moreover, a 4-mm left
external iliac lymph node (white arrow) was almost not visible on axial T2-weighted imaging (E) but had focal uptake on fused imaging
(F), which was very suspicious for pelvic nodal recurrence.
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to targeted therapy (mainly radiotherapy) in 32% of patients
or conversion to systemic treatment (mainly ADT) in approxi-
mately 10% of patients. Few studies have addressed better
treatment plan based on salvage treatment in oligometastatic
patients (with bone and/or nodal involvement) with pelvic
lymphadenectomy (44) or PSMA-guided radiation therapy
(45,46). Calais et al. (8) showed that even when pelvic lymph
node stations were included in standard radiotherapy plans
for salvage BCRo 1.0 ng/mL, 19% of patients had metastasis
(nodal and/or bone) outside the radiation delineation area
determined based on CTalone. A complementary study showed
that when PSMA PET identified positive lymph nodes, the
standard radiotherapy response was 62% compared to 85%
when PSMA PET was negative for nodal involvement (47),
demonstrating the possibility of generating tailored radiation
plans guided by PSMA imaging.
Despite these promising results on the clinical impact of
changing management based on PSMA PET evaluation of
BCR, improvement in long-term outcomes must be demon-
strated to confirm that this transformational molecular imaging
technique is useful in clinical practice. As recently discussed in
an editorial article published in the Journal of Nuclear Medicine
(48), the major challenge oncologists face in managing PCa is
identifying which patients harbor significant and nonsignificant
recurrence. Current treatment options have rather low success
in curing patients, and avoiding toxicity and promoting quality
of life are fundamental objectives in treatment selection.
Assessment of therapeutic response
Numerous therapeutic modalities are available for early or
advanced PCa. Various options including local to systemic
treatments can be used in a multitude of clinical scenarios.
Furthermore, beyond the efficacy of each treatment modality,
toxicities and costs play important roles in therapeutic deci-
sions and adequate management of PCa, creating a demand
for precise assessment of therapeutic benefits. In this setting,
imaging can provide helpful information about residual
disease extension, the degree/depth of response, biological
heterogeneity/behavior of neoplasia, disease progression
and even side effects (49). Therefore, assessing therapeutic
responses in PCa is a complex issue, since each stage of
disease has very specific features and requires different
approaches. Localized disease can be treated with surgery or
radiotherapy and followed by active surveillance with
comparable outcomes (50). Advanced disease encompasses
a large spectrum of tumoral phenotypes and clinical condi-
tions, varying from favorable oligometastatic (29) presenta-
tions to disseminated metastatic disease; each situation requires
different treatments, such as hormones, radiation or chemo-
therapy. However, both localized and advanced prostatic
disease are under the influence of androgen receptor (AR)
signaling, which is a crucial driving pathway for growth and
proliferation of PCa cells and the main target for ADT (51).
An important condition is metastatic castration resistant PCa
(mCRPC), which is characterized by persistent AR stimulation
independent of ADT (52) and is frequently associated with
disseminated disease and a poor prognosis (53). In mCRPC,
an important characteristic that favors imaging is that serum
PSA, a consolidated surrogated marker of disease progression,
can be dissociated from real burden of metastatic disease (49).
Traditional and newer imaging techniques. Tradition-
ally, the effects of local therapies (i.e., radiotherapy) have been
evaluated by MRI (54,55) (more in the context of suspicion of
recurrence than for response evaluation), while systemic
treatments are evaluated by CT (especially by means of the
Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
criteria) (56) and BS (57). However, despite the wide usage,
good reproducibility and consolidated reimbursement of these
approaches, they have several limitations including pitfalls
for evaluating treated prostate glands, the low specificity of
MRI (54), the low sensitivity of CT for normal sized lymph
nodes and bone lesions, and drawbacks of BS, which are
mostly related to its low spatial resolution, susceptibility to
‘‘flare’’ phenomenon and indirect measurement of bone meta-
static activity (i.e., assessing only the reaction of normal bone
to an injury caused by metastasis, leading to a loss of accuracy
in assessment of therapeutic responses) (58).
The increasing availability of new imaging techniques and
modalities has changed this landscape. By mixing anatomical
and functional features (especially with the use of DWI), mpMRI
has allowed a new perspective on predicting and evaluating
responses after radiotherapy (59) and ADT for locoregional
disease (55). BS methods for quantitatively evaluating the whole
skeleton have allowed the development of biomarkers and
added prognostic power to this commonly used methodology
(60). More recently, whole-body MRI, based on DWI sequences,
has been proposed for evaluating treatment responses in
patients with bone metastases and has shown promising
results (61); this technique has been included in recent standard-
ization procedure guidelines (62) despite its low availability
and some limitations related to low specificity (63). In this evolv-
ing scenario, PET imaging, as a relatively recently developed
modality, has shown great value in PCa management. Despite
some initial disappointment and lessons learned with use
of FDG PET and PET/CT for evaluating PCa (64), precise
comprehension of tumor biology and appropriate patient
selection have provided valuable knowledge, allowing the
rational use of this technology for selected indications (65),
and, more importantly, have paved the way for molecular imag-
ing with others tracers (i.e., 18F-choline and 18F/68Ga-PSMA)
for PCa evaluation, specifically in assessment of therapeutic
responses. Parallel to the development of new tracers t, the
conception of new hybrid PET/MRI equipment has brought
a new perspective of synergy of the strengths of each
modality (66).
PSMA PET/MRI. How does the PSMA PETcomponent of
PSMA PET/MRI add value to the assessment of therapeutic
responses?
PSMA is overexpressed in aggressive, poorly differenti-
ated and metastatic PCa (67), a characteristic that confers
enormous potential for using this molecular imaging marker
to evaluate progression of disease. However, different from
FDG, which appears to have predictable uptake and a posi-
tive correlation with AR status (68) of neoplastic cells (Figure 3),
PSMA expression has some particularities, especially related
to AR signaling and blocking of ADT (69). As addressed by
previous preclinical (51,69) and clinical (67) reports, PSMA
expression in PCa cells can rapidly increase after AR inhibition
in hormone-sensitive PCa (69), leading to potential misinter-
pretation of PET/MRI or PET/CTscans for therapeutic assess-
ment. On the other hand, therapeutic effect (i.e., reduction
in the neoplastic cell population) along with ADTcan be accu-
rately assessed with PSMA PET several months after initiating
therapy (70) (Figure 4), raising the unanswered question of
when the turning point from initial PSMA overexpression to
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decreased overall expression due to reduction in the neo-
plastic cell population occurs. Given that ADT is one of the
cornerstones of current PCa management, further studies are
expected in this area.
For other treatment modalities, such as radiotherapy (includ-
ing the growing indications for stereotaxic radiotherapy for
oligometastases (71)), chemotherapy (72) and radionuclide
therapies (with 177Lu/225Ac-PSMA or 223Ra) (73), PSMA
expression appears to be more directly linked with disease
status and therapeutic effects, showing a good correlation
with PSA values and emerging as a promising imaging tool
and a potential prognostic biomarker.
As many reports using PSMA PET/MRI or PET/CT to
assess treatment response have emerged, a critical issue needs
to be addressed: standardization. Using established data for
FDG, many authors have extrapolated the PET Response
Criteria in Solid Tumors (PERCIST) criteria (74) to PSMA PET
(71,72) with satisfactory but still very preliminary results.
Like in FDG PET for other types of neoplasia, interesting
whole-body quantification algorithms have been proposed for
PSMA PET, and many of them are focused on calculating
the burden of bone disease, its variations along during treat-
ment and correlation with consolidated surrogated biomarkers
(i.e., PSA) with exciting initial results (75). Given the prog-
nostic importance of bone metastases in the natural progres-
sion of PCa, due to the a lack of robust criteria for evaluating
the responses bone metastases and the limitations BS limita-
tions, whole-body quantitative algorithms are a promising
area for PSMA PET, particularly PSMA PET/MRI applications
for PCa management.
How does the MRI component of PSMA PET/MRI add
value to assessment of therapeutic responses?
The main focus of this paper is to discuss potential PSMA
PET/MRI applications for PCa. The main strength of PSMA
PET, as previously discussed, is powerful molecular in vivo
tumor characterization with high sensitivity and specificity.
MRI is a consolidated morphological imaging method that
provides excellent characterization of anatomical and soft tissue
contrast, and its strengths are not limited to this. MpMRI,
which has incorporated functional sequences, has assumed a
Figure 3 - Example of different biological behaviors of PCa with treatment assessed by different tracers: (A) FDG PET in patient with
advanced PCa showing retroperitoneal nodal and diffuse bone disease; (B) After beginning ADT, FDG PET shows a marked reduction in FDG
uptake in the lesions; (C) PCa has become resistant to castration. Note subtle increase in diffuse FDG uptake in the skeleton. (D) At the same
timepoint as C, PSMA PET was performed, showing marked bone disease, leading to an improved assessment of disease extension; and
(E) PSMA PET performed 4 months after chemotherapy shows partial reduction in PSMA expression of diffuse skeletal involvement.
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central role in PCa management. Functional sequences,
mainly DWI, have high sensitivity (despite low specificity)
for detecting and characterizing neoplastic tissue with local-
ized or whole-body imaging, and have comparable perfor-
mance to PET radiotracers for regions such as bone marrow (76).
As with PET imaging, DWI requires quantification, mainly
through apparent diffusion coefficient (ADC) maps.
In summary, relatively little early data are available regard-
ing PSMA PET/MRI for assessment of therapeutic response in
PCa. Despite the great potential of this modality and encour-
aging preliminary results, further trials are necessary to
provide a better clinical understanding of PSMA expression
behavior compared various therapies modalities (mainly
ADT), to optimize molecular and functional response criteria
and to improve both PET and MRI quantitative algorithms.
PSMA PET imaging represents an important breakthrough
in molecular imaging for PCa evaluation. Regardless the
PSMA ligand used, this emerging diagnostic modality offers
substantial advantages over conventional diagnosis in differ-
ent clinical settings. For lesion detection, PSMA PET/MRI
might complement MRI alone for identifying clinically signifi-
cant tumors and possibly for selecting target lesions in the
clinical scenario of a persistent suspicion of PCa with a pre-
viously negative biopsy. At diagnosis, PSMA PET/MRI adds
value to N and M staging, with notable clinical impact on
patient management, especially in intermediate- and high-risk
patients. In the context of BCR, PSMA PET/MRI has its most
robust application, combining the molecular information from
PETwith the morphofunctional data from MRI, including the
gold standard MR perfusion. Finally, PSMA PET imaging has
been studied as an imaging biomarker of tumor responses
with some encouraging but still preliminary results.
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